POTENTIAL OF URAI MATHIRAI (PEDIATRIC SIDDHA FORMULATION) FOR THE PROPHYLAXIS AND MANAGEMENT OF COVID-19 IN CHILDREN
NAINA MOHAMED PAKKIR MAIDEEN *
Dubai Health Authority, Dubai, UAE.
GOBINATH MANAVALAN
Department of Pharmaceutical Chemistry, Ratnam Institute of Pharmacy, Nellore, AP, India.
KUMAR BALASUBRAMANIAN
Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Nellore, AP, India.
S. NIVEDHITHA
Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Nellore, AP, India.
M. THIRUMAL
Department of Pharmacognosy, SRM College of Pharmacy, Chennai, TN, India.
S. VASANTH KUMAR
Department of Pharmaceutics, KK College of Pharmacy, Gerugambakkam, TN, India.
RAJKAPOOR BALASUBRAMANIAN
Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Komarapalayam, TN, India.
*Author to whom correspondence should be addressed.
Abstract
The World Health Organization (WHO) data proposes that 8.5% of reported COVID-19 cases belong to pediatric population who are aged less than 18 years. Supportive care alone is recommended in asymptomatic, mild, or moderate pediatric COVID-19 patients by the panel of pediatric infectious diseases physicians and pharmacists from 20 geographically diverse North American institutions. This review article focuses on the prophylactic and therapeutic potential of Urai mathirai in the management of pediatric COVID-19 patients. The literature was looked, in databases such as Medline/PubMed Central/PubMed, Google Scholar, Science Direct, Web of science, Directory of open access journals (DOAJ), and reference lists to distinguish published manuscripts relevant to the use of Urai mathirai to prevent or treat COVID-19 in children. The herbs found in Urai Mathirai and their bioactive phytoconstituents possess antiviral, anti-inflammatory, antioxidant, immunomodulatory, bronchodilatory and other pharmacological effects relevant to the management of signs and manifestations of COVID-19. The viability of Urai Mathirai in the prophylaxis and management of pediatric COVID-19 patients could further be established by future clinical studies.
Keywords: SARS CoV-2, COVID-19, pediatric siddha formulations, urai mathirai, herbal formulations